Congruence Announces Participation at the 2026 Bloom Burton & Co. Healthcare Investor Conference
https://www.prnewswire.com/news-releases/congruence-announces-participation-at-the-2026-bloom-burton--co-healthcare-investor-conference-302747214.html
Congruence Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
https://www.prnewswire.com/news-releases/congruence-announces-participation-in-the-25th-annual-needham-virtual-healthcare-conference-302738712.html?tc=eml_cleartime
Congruence Announces $39.5M Financing to Advance Portfolio of Small Molecule Correctors into the Clinic
https://www.prnewswire.com/news-releases/congruence-announces-39-5m-financing-to-advance-portfolio-of-small-molecule-correctors-into-the-clinic-302718764.html?tc=eml_cleartime
Congruence Announces First Dosing in Phase 1/1b Clinical Trial of CGX-926, a First-in-Class Oral MC4R Corrector for Genetic Obesity
https://www.prnewswire.com/news-releases/congruence-announces-first-dosing-in-phase-11b-clinical-trial-of-cgx-926-a-first-in-class-oral-mc4r-corrector-for-genetic-obesity-302718759.html?tc=eml_cleartime
Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
https://www.prnewswire.com/news-releases/congruence-and-ono-pharma-expand-multi-target-research-partnership-with-the-addition-of-two-new-programs-302701525.html
Congruence Therapeutics to Present Preclinical Characterization of its MC4R Corrector Development Candidate CGX-926 for Genetic Obesity at ObesityWeek 2025
https://www.prnewswire.com/news-releases/congruence-therapeutics-to-present-preclinical-characterization-of-its-mc4r-corrector-development-candidate-cgx-926-for-genetic-obesity-at-obesityweek-2025-302607289.html
Congruence Therapeutics Earns “Fierce 15” Distinction for 2025
https://www.prnewswire.com/news-releases/congruence-therapeutics-earns-fierce-15-distinction-for-2025-302562951.html
Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial
https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime
Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations
https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime
Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit
https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime